Glaxo Canada
Executive Summary
Research collaboration with Canadian biotech firm Allelix Biopharmaceuticals will focus on bone disorders, including osteoporosis, bone cancer and bone fractures. Glaxo Canada is providing a minimum of $ 10 mil. over five years. One of the first projects will be the production via genetic engineering of parathyroid hormone, for use in treating osteoporosis. Allelix is also investigating the cytokine interleukin-6 for inflammation under an agreement with Rhone-Poulenc.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.